Approved For Release 2003/09/10 : CIA-RDP96-00792R000100140042-6

of fund at 120th for Bosaug 23

Ille Cige

August 2, 1983

IAG PA-F-SA

SUBJECT: Identification of Selected Personnel (U)

Dr. Harold E. Puthoff SRI International 333 Ravenswood Avenue Menlo Park, California 94025

Dear Dr. Puthoff:

(S/CL-1/NOFORN) Reference your memorandum, dated 11 May 1983, Subject: Selection/Training Task.

(U) The attached draft Statement of Work is forwarded for your review.

(S/CL-1/NOFORN) Request specific cost, expected length of each phase and any recommended additions which may be necessary within the Statement of Work as drafted.

(U) To allow sufficient time to meet administrative requirement for funding in FY 83, request an expeditious response.

Sincerely,

Arederick H. Atwater Acting Project Manager

RDP96-00792R000100140042-6

Enclosure

GENTER ADDA

OR IG INATOR CONTROLLED

CLASSIFIED BY: CG, INSCOM DECL: OADR

WARNING NOTICE CENTER LANE SPECIAL ACCESS PROGRAM RESTRICT DISSEMINATION TO THOSE WITH VERIFIED ACCESS CATEGORY 3

NOT RELEASABLE TO FOREIGN NATIONALS

For Release 200

Approved For Release 2003/09/10 : CIA-PDP96-00792R000100140042-6

的编制的"Farer",在教育的"新闻》的"Ander Ander The Ander The Ander Ander

STATEMENT OF WORK

1. (U) GENERAL

1.1 (S/CL-3/NOFORN/ORCON) The objective of this effort is to investigate a particular aspect of psychoenergetics relating to operational management of personnel. That is; determine if a personality testing technique can be created which when applied to a general population will delineate specific individuals who exhibit a higher degree of talent for Remote Viewing (RV).

1.2 (U) MAJOR GOALS ARE:

(a) (S/CL-3/NOFORN/ORCON) PHASE I: Apply personality testing with proven remote viewer personnel from SRI and Project CENTER LANE; and determine testing profile(s) which can be used to identify personel with an aptitude for remote viewing.

(b) (S/CL-3/NOFORN/ORCON) PHASE II: Test these same individuals with "self-report" type tests, and compare the results of these with the previously identified profile(s) to determine testing accuracy. Apply the identified profile(s) against a general test population and segragate persons who show a talent for remote viewing from those who do not.

(c) (S/CL-3/NOFORN/ORCON) PHASE III: Test the personnel who show a talent for remote viewing against randomly selected targets; test the personnel who did not show a talent against the same targets.

(e) (S/CL-3/NOFORN/ORCON) Provide an overall evaluation of the above three Phases with conclusive recommendations. If the first two Phases produce negative results; an overall evaluation of those two phases will be made to include a recommendation for further action.

2. (U) SPECIFIC TASKS:

2.1 (U) PHASE I - As follows:

(a) (S/CL-3/NOFORN/ORCON) Collect personality profile data from proven remote viewers. Data will be collected from proven personnel; both at SRI as well as Project CENTER LANE.

NOT RELEASABLE TO FOREIGN NATIONALS



Approved For Release 2003/09/10 : CIA-RDP96-00792R000100140042-6



(b) (U) Data will be collected by using an extended Wechsler Test.

(c) (U) Testing will be carried out under laboratory conditions by two experienced testors; Dr. David Saunders, MARS Measurements Association (SRI Consultant), Lawrenceville, New Jersey; and Dr. Michael Hecker (an SRI Staff Member.)

(d) (U) The data obtained will be analyzed in accordance with the P.A.S. (Personality Assessment System) concept.

(e) (U) The above analysis will provide the basis upon which specific and appropriate personality profile(s) of interest will be designated and those will be extrapolated for use during PHASE III.

(f) (U) Provide an interim report of findings from PHASE I.

2.2 (U) PHASE II - Will be run in parallel with PHASE I and includes the following:

(a) (S/CL-2/NOFORN/ORCON) Self-report data will be collected from the selected individuals within SRI and the CENTER LANE Project. These will be the same individuals selected for testing under PHASE I.

(b) (U) The self-report data will be determined from tests such as the Myers-Briggs and 16 PF questionnaire. Testing will be under laboratory conditions and will be utilized to design a pre-screening questionnaire.

(c) (U) Analysis of the self-report data will be carried out using the B. P. S. (Behavior Prediction System) concept to generate a scoring key capable of extracting those individuals with profile(s) indicated within PHASE I, as being profile(s) of interest.

(d) (S/CL-3/NOFORN/ORCON) The self-report test criteria will be applied against a general population. The general population will contain the previously selected SRI and CENTER LANE Remote Viewer personnel.

(e) (U) To test whether the pre-screening (self-report) test is effective in selecting individuals with the PHASE I profiles, a second group of individuals will be given both the pre-screening and extended Wechsler tests under like laboratory conditions and the correlations between these results and the previous results will be evaluated and examined.

NOT RELEASABLE TO FOREIGN NATIONALS

Approved For Release 2003/09/10 : CIA-BDP96-00792R000100140042-6

(f) (U) Provide an interim report of findings from PHASE II.

2.3 PHASE III - Assuming success in Phases I and II the following will be accomplished:

(a) (S/CL-3/NOFORN/ORCON) The appropriate profile(s) developed through testing during PHASES I & II will be used to delineate individuals into two groups. Those with remote viewing potential as well as those who do not show potential.

(b) (S/CL-3/NOFORN/ORCON) Personnel who show potential in remote viewing will then be tested under laboratory conditions against a randomly selected group of targets.

(c) (S/CL-3/NOFORN/ORCON) Personnel not selected as having potential will also be run under laboratory conditions against the same selected group of targets.

(d) (S/CL-3/NOFORN/ORCON) A comparison of both groups of personnel will then be made to determine the validity of slection criteria developed and presented from PHASES I & II.

(e) (S/CL-3/NOFORN/ORCON) Should it be proven by failure in PHASES I & II that a personality profile cannot be developed which will assist in selecting appropriate remote viewer personnel; then PHASE III will be canceled with the concurrance of the sponsor and all monies left transferred to on-going remote viewer training.

3. (U) SECURITY

GENTER LANE

-

Military security requirements in the performance of this contract shall be maintained in accordance with the CENTER LANE SECURITY PROCEDURES GUIDE, dated; Ol March 1983 (S/CL-1/NOFORN ORCON); and DD Form 254 attached hereton. The highest classification involved in the performance of this contract is SECRET/CL-4/NO FOREIGN DISSEMINATION/ORIGINATOR CONTROLLED.

4. (U) DELIVERABLES: The contractor will provide the following:

4.1 (S/CL-1/NOFORN/ORCON) State-of-the-art information on selection of personnel with a talent for Remote Viewing (RV).

4.2 (S/CL-3/NOFORN/ORCON) Progress report (2 copies): A written evaluation of findings within 10 days of completion of Phase I, development of/and use of psychological profile(s) testing.

NOT RELEASABLE TO FOREIGN NATIONALS

Approved For Release 2000/09/10 CIA RDP96-00792R000100140042-6

4.3 (S/CL-3/NOFORN/ORCON) Progress report (2 copies): A written evaluation of findings within 10 days of completion of Phase II, development of/and use of self-report testing; to include comparison for accuracy against Phase I testing, and use of the newly designed pre-screening questionnaire.

4.4 (S/CL-3/NOFORN/ORCON) A final report (3 copies) will be furnished within 30 days following completion of the overall evaluation of developed Selection Testing Methodology. Report will include but is not limited to the following:

(a) (S/CL-3/NOFORN/ORCON) Report will include a summary of tests performed in each methodology area; an evaluation of those tests; and a written comparison of one test methodology to another.

(b) (S/CL-3/NOFORN/ORCON) Report will provide findings which result from the application of testing methodologies against a general population to select remote viewers. This will include an evaluation of remote viewing results as produced by those personnel identified as talented, as well as results from those who were not identified as talented.

(c) (S/CL-3/NOFORN/ORCON) Report will provide a summary of recommended testing for future selection of remote viewer personnel based upon the above.

- 6. (U) SPECIAL REQUIREMENTS
 - 6.1 (U) Use of Human subjects:
 - (a) (U) The following definitions are used:

(1) (U) At risk means that the human subject may be exposed to the possibility of harm - physical, biological, psychological, sociological, or other as a consequence of an act or omission that goes beyond the application of those established and accepted methods or procedures which are in his best interests, or that increases ordinary risks of daily life, including the recognized risks inherent in his chosen occupation or field of service.

(2) (U) Human subject means any human being who, knowingly or unknowingly, is subjected to an act or omission, whether at risk or not, the object of which is to contribute to knowledge to be gained as a part of work to be performed under the scope of this contract.

Approved For Release 2003/09/10 : CIA-RDP96-00792R000100140042-6

N. LEEL

NOT RELEASABLE TO FOREIGN NATIONALS

الم المراجع المراجع الم

(b) (U) The contractor, before undertaking to perform any study involving human subjects, whether at risk or not, shall insure that the following minimum conditions are complied with:

(1) (U) The proposed study has been reviewed and approved by a committee meeting the requirements set forth in Chapter 46 of Title 45 of the Code of Federal Regulations.

(2) (U) The number of human subjects used will be kept to the minimum number that will reasonably achieve the required results.

(3) (U) The study must be such as to contribute significantly to scientific knowledge and have reasonable prospects of yielding important results essential to an Army research program.

(4) (U) The study will be conducted only by persons possessing the requisite scientific qualifications. The highest degree of skill and care will be required during all stages of study of persons who conduct or assist in the study.

(5) (U) The subject will be informed that at any time during the course of his participation he has the right to revoke his consent and withdraw from participation without prejudice to himself.

(6) (U) Participation by subjects will be immediately terminated if it subsequently appears that the risk to the subjects is significantly greater than anticipated at the time review and approval was granted.

(7) (U) There shall be no greater intrusion into the privacy of the human subject than is absolutely necessary for the conduct of the study involved. Except for the submission of reports and other data required by this contract, any information obtained about human subjects as a result of participation shall be held as confidential as the law allow.

(8) (U) The study will be conducted so as to avoid all unnecessary physical or mental suffering or injury.

(9) (U) No study will be conducted if there is any inherent reason to believe that death or disabling injury is likely to occur. Sufficient animal or laboratory experiments, or other evaluations, must have been completed to give assurance of acceptable risks prior to the use of human subjects.

NOT RELEASABLE TO FOREIGN MATIONALS

or Release 2003/09/10 : CIA-RDP96-00792R000100140042-6



(10) (U) The degree of risk to be taken will never exceed that which is justified by the benefit to the subject and/or the humanitarian importance of the knowledge to be gained.

(11) (U) A physician will be responsible for the medical care of subjects. Even if not the project leader, the physician will have authority to terminate the study at any time that he believes death, injury or harm is likely to result.

(12) (U) Proper preparations will be made, and adequate facilities provided to protect the subject against all foreseeable possibilities if injury, disability or death. This includes but is not limited to hospitalization and medical treatment as may be required. In addition, all apparatus and instruments necessary to deal with likely emergency situations will be available.

(13) (U) Human subjects will have no physical or mental conditions which will make participation more hazardous for them than it would be for normal healthy persons, unless such condition is a necessary prerequisite for the particular study involved. In any such case, the use of human subjects with such pre-existing conditions must have been specifically described and justified in the scope of the work to be performed under this contract.

(14) (U) The scientifically qualified person conducting the study, and each member of his research team, will be prepared to terminate the subject's participation at any stage if he has reason to believe, in the exercise of the good faith, superior skill, and careful judgment required of him, that continuation is likely to result in injury, disability, or death to the human subject.

(c) (U) The contractor, before permitting any person to participate as a human subject, whether at risk or not, shall insure that the following minimum conditions are complied with:

(1) (U) Legally effective informed consent will be obtained by adequate and appropriate methods in accordance with the provisions of this clause.

(2) (U) All consent must be voluntary. It must be the knowing consent of the individual or his legally authorized representative, so situated as to be able to exercise free power of choice without there having been any use of force, fraud, deceit, duress, constraint, coercion, or lawful or improper inducement. The elements of information necessary to such consent include:

CIA-RDP96-00792R000100140042-6

NOT RELEASABLE TO FOREIGN BATIONALS

GENTER Approved For Release 2003/09/10

Approved For Release 2003/09/10 : CIA-RDP96-00792R000100140042-6

(i) (U) A fair explanation of the procedures to be followed, and their purposes, including identification of any procedures which are experimental.

(ii) (U) A description of any attendant discomforts or risks reasonably to be anticipated.

(iii) (U) A description of any benefits reasonably to be anticipated.

(iv) (U) A disclosure of any appropriate alternative procedures that might be advantageous to the subject.

(v) (U) An offer to answer any questions concerning the procedure.

(vi) (U) An instruction that the subject is free to revoke his consent and to discontinue participation at any time without prejudice to himself.

(d) (U) Exculpatory language through which the subject is made to waive, or appear to waive, any of his legal rights, including any release from liability for negligence, is prohibited.

(e) (U) Prior consent by a subject or his legally authorized representative shall be obtained in all cases. Such consent shall be in writing whenever it is reasonably possible to do so. The consent form may be read to the subject or his legally authorized representative, but in any event he or his legally authorized representative must be given adequate opportunity to read it and to ask questions they might have. This consent form should then be signed by the subject or his legally authorized representative and by a witness not directly involved in the study. Oral consent may be used only when it has been specifically described and justified in the scope of the work to be performed under this contract or approved in writing by the contracting officer. When so authorized and used, oral consent is subject to all the same standards as apply to written consent, except that the signature of the subject or his legally authorized representative is not required.

(f) (U) Prior to conduct of the study, the contractor shall submit for approval to the contracting officer's representative a detailed description of the means by which informed consent will be obtained, to include any forms to be used. Upon completion of the study, the contractor will submit to the contracting officer's representative a detailed report demonstrating compliance with paragraph (c), to include copies of the written consent if such was obtained.

NOT RELEASABLE TO POHALON MARIE

Approved For Release 2003/09/10 : CIA-RDP96-00792R000100140042-6

U.S. Ash J.

Approved For Release 2003/09/10 : CIA-RDP96-00792R000100140042-6

(g) (U) The contractor shall not undertake to conduct either the clinical pharmacology or clinical trails of an investigational drug unless this contract contains the clause entitled "Clinical Study of Investigational Drugs."

(h) (U) Prisoners of war will not be used under any circumstances.

6.2 (U) DoD Directive 5240.1-R governing experimentation on human subjects will be followed by the contactor. Informed consent of all subjects will be obtained in writing in accordance with the guidelines issued by the Department of Health, Education and Welfare. All persons participating as human subjects, as defined in paragraph 6.1 above shall be known to possess the abilities and qualities which will be observed and analyzed during the conduct of this contract.



NOT RELEASABLE TO FOREIGN NATIONARS

Approved For Release 2003/09/10 : CIA-RDP96-00792R000100140042-6